Differences in lung bioavailability between different propellants for fluticasone propionate.

Wilson, A M; Sims, E J; Orr, L C; Lipworth, B J · Lancet · 1999

rct · Level II

Where this comes from

Abstract

The lung bioavailability (as adrenal suppression) of fluticasone propionate was about twofold greater with chlorofluorocarbons than hydrofluoroalkane as propellant. Direct switching between formulations on a microg equivalent may therefore be inadvisable.

Medical subject headings